PMGC Holdings Inc. (NASDAQ:ELAB) has announced full compliance with Nasdaq's minimum bid price requirement, following a warning of non-compliance received in November 2024. The pharmaceutical company, previously known as Elevai Labs Inc., also reported the rebranding of two of its wholly-owned subsidiaries. According to InvestingPro data, the company's stock has experienced significant volatility, with the price declining over 99% in the past year, highlighting the importance of this compliance achievement.
The Nasdaq compliance issue arose when PMGC Holdings' stock price fell below the Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement. In response, the company was granted an exception by Nasdaq, with the condition that it would execute a reverse stock split by December 26, 2024, and demonstrate compliance by January 9, 2025. On January 14, 2025, PMGC Holdings received a Compliance Letter from Nasdaq confirming that the company had successfully met the bid price requirement. Despite recent challenges, InvestingPro analysis shows the company maintains strong gross profit margins of 71% and a healthy current ratio of 3.86, indicating solid short-term liquidity.
In addition to resolving the compliance issue, PMGC Holdings Inc. also announced name changes for two of its subsidiaries. Effective January 10, 2025, Elevai Research Inc. became PMGC Research Inc., and on January 14, 2025, Elevai Biosciences, Inc. was renamed Northstrive Biosciences Inc. These changes are part of the company's broader rebranding strategy.
The corporate actions, including the reverse stock split and the subsidiary rebranding, are part of PMGC Holdings' efforts to maintain its listing on the Nasdaq Stock Market and to align its brand identity across its operations. The company, headquartered in Newport Beach, California, specializes in pharmaceutical preparations and operates under the jurisdiction of Delaware.
This news is based on the latest 8-K filing by PMGC Holdings Inc. with the United States Securities and Exchange Commission. The information provided is intended to give shareholders and the investment community insight into the company's regulatory compliance and its operational adjustments. InvestingPro subscribers can access 13 additional ProTips and comprehensive financial metrics to better understand PMGC Holdings' market position and growth potential.
In other recent news, PMGC Holdings has seen a series of significant developments. The company has undergone leadership changes at its subsidiaries, including the resignation of Jordan Plews as Director. Graydon Bensler has assumed the CEO role at Elevai Research Inc., with Braeden Lichti stepping in as Chairman. PMGC Holdings has also completed its reincorporation from Delaware to Nevada, with HTL International, LLC taking over as the new independent registered public accounting firm.
In terms of acquisitions, Carmell Corporation has purchased assets from PMGC Holdings' subsidiary, Elevai Skincare Inc., for approximately $1.1 million. This acquisition includes Elevai's skincare and haircare business, which has a trailing twelve-month revenue of about $2.5 million.
PMGC Holdings' subsidiary, Elevai Biosciences, is prepping for a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration for its novel obesity treatment, EL-22. The company has also signed a Master Services Agreement with KCRN Research, Inc. to support the development of EL-22. These are the recent developments in the companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.